BrightView Holdings, Inc. (BV)
Live price chart, market sentiment, and community perspectives for BrightView Holdings, Inc. (NYSE: BV).
Live price chart, market sentiment, and community perspectives for BrightView Holdings, Inc. (NYSE: BV).
From a risk management standpoint, the contraction in Adjusted EBITDA to $96.1 million—down from $113.2 million—cannot be ignored. Management attributes this drop to a nonroutine insurance adjustment and higher fuel costs, but these variable input costs directly compress net margins, which dropped to 0.9% this quarter. Anyone looking to long the commercial landscaping sector needs to factor in these margin squeezes before deploying capital.
On our desk, we are closely monitoring the heavy short interest, which currently sits at a staggering 42.0% of the float. Even though the analyst consensus holds a Buy rating with an average price target of $16, the recent Q3 2026 earnings miss ($0.17 EPS reported vs. $0.28 consensus) gives bears the upper hand in the near term. Morgan Stanley calling this a 'step back' in the turnaround narrative adds substantial overhead resistance to any immediate upward momentum.
When evaluating BrightView's operational turnaround, my quantitative model focuses heavily on leading indicators like the 250 basis point year-over-year improvement in customer retention, now hitting 84.6%. Furthermore, the 4% expansion in the contract book since Q2 2025 provides solid baseline visibility for sustainable mid-to-upper single-digit growth, assuming frontline execution remains stable.
As a hedge fund portfolio manager, I see a classic divergence between fundamental operational progress and headline earnings misses. BrightView just delivered its second consecutive quarter of land maintenance revenue growth (reaching $514.5 million, up 2.3% YoY), and frontline employee turnover dropped by 7 percentage points. Yet, the market punished the stock due to the EPS shortfall and the unexpected insurance adjustment.
Watching the 50-day moving average and short-term price reactions following Oppenheimer's recent price target adjustment to $16 from $17. With 9 analysts covering the stock and a highest target of $22 alongside a lowest target of $11, the valuation dispersion is wide. Hedging with protective put options makes sense given the 42% short float vulnerability around macroeconomic swings.
Explore plasma cleansing, somatic organ swaps, and BCI.